SCHEMBL25835438

SCHEMBL25835438

CC/C=C\CCCC(=O)NCCOCCN

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 7/20 0.57
▸ SLC6A5 Q9Y345 2/20 0.51
▸ LPAR1 Q92633 2/20 0.47
▸ LPAR2 Q9HBW0 2/20 0.47
▸ ENPP2 Q13822 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ FAAH O00519 2/20 0.46
▸ CNR2 P34972 2/20 0.46
▸ TRPM8 Q7Z2W7 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KCNK3 O14649 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TRPV1 Q8NER1 1/20 0.46
▸ MAPT P10636 2/20 0.45
▸ EPHX2 P34913 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15124347 0.96 CNR1 (0.64) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL15124580 0.95 CNR1 (0.63) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL15253048 0.87 CNR1 (0.62) CNR1ALDH1A1FAAHCNR2MAPT
SCHEMBL15124107 0.87 CNR1 (0.62) CNR1ALDH1A1FAAHCNR2MAPT
SCHEMBL15124241 0.86 CNR1 (0.61) CNR1ALDH1A1FAAHCNR2MAPT
SCHEMBL4392061 0.86 SLC6A5 (0.71) CNR1SLC6A5LPAR1LPAR2ENPP2
SCHEMBL30571243 0.85 CNR1 (0.70) CNR1SLC6A5ALDH1A1FAAHCNR2
SCHEMBL31378237 0.85 CNR1 (0.70) CNR1SLC6A5ALDH1A1FAAHCNR2
SCHEMBL10028552 0.85 SLC6A5 (0.69) CNR1SLC6A5LPAR1LPAR2ENPP2
SCHEMBL26032862 0.83 SLC6A5 (0.66) CNR1SLC6A5LPAR1LPAR2ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 — — US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 CNR1 4510/4885SLC6A5 4323/4885LPAR1 147/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 CNR1 4167/4885SLC6A5 4369/4885LPAR1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback